Cataract
Conditions
Keywords
Lens Fragmentation, Cataract, Phacoemulsification, Femtosecond Laser
Brief summary
This clinical study is a controlled, open, prospective, single-centre, multi-surgeon eye study to determine the safety and efficacy of intraocular cuts for femtosecond laser assisted lens frag-mentation to support phacoemulsification of the cataractous lens prior to IOL implantation. The cuts are applied by means of the FEMTEC femtosecond laser system with the CustomLens soft-ware module using a cylindrical and radial cut pattern with diameter and height dependent on anterior chamber depth, pupil diameter and ocular lens size. The hypothesis of the study is that by means of femtosecond laser assisted lens fragmentation the required ultrasound energy used for phacoemulsification can be reduced in a safe and effective way.
Interventions
PROCEDURELens Fragmentation by means of a femtosecondlaser
In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
PROCEDUREManual Phacoemulsification
Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
Sponsors
Technolas Perfect Vision GmbH
Study design
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Clear corneal media * Patients must be at least 18 years of age.
Exclusion criteria
* On a keratometric map of the cornea, the minimal and maximal K-values of the central 3mm zone must not differ by more than 5 dioptres. (exclusion criterium for Group A only) * The maximum K- value may not exceed 60 D, the minimal value may not be smaller than 37 D. (exclusion criterium for Group A only) * Corneal disease or pathology that precludes transmission of laser wavelength or distortion of laser light. (exclusion criterium for Group A only) * Subjects with a poorly dilating pupil or other defect of the pupil that prevents the iris from adequate retraction peripherally. * Lens/zonular instability such as, but not restricted to, Marfan's Syndrome, Pseudoexfoliation Syndrome, etc. * Previous intraocular or corneal surgery of any kind, including any type of surgery for either refractive or therapeutic purposes in either eye. * Known sensitivity to planned concomitant medications. * Patients with disorders of the ocular muscle, such as nystagmus or strabismus * Keratoconus * Patients with woundhealing disorders such as connective tissue disease, autoimmune illnesses, immunodeficiency illnesses, ocular herpes zoster or simplex, endocrine diseases, lupus, rheumatoid arthritis * Abnormal examination results from slit lamp, Fundus, IOL Master * Abnormal examination results from Orbscan (exclusion criterium for Group A only) * Patients with an autoimmune disease, collagenosis or clinically significant atopy. * Patients who are pregnant or nursing. * Patients who do not give informed consent. * ACD \< 2.4 mm or ACD \> 4.5 mm as measured by ultrasonic examination (exclusion criterium for Group A only)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Observation of the applied Effective Phaco Time (EPT) for Pahcoemulsifikation during surgery. The observed Effective Phaco Time in Group A should be significantly lower than in group B. Statistically significant difference at p<0.05. | at time of surgery |
Secondary
| Measure | Time frame |
|---|---|
| Less or equal adverse events in Group A compared to group B (e.g. retinal detachment, IOL malposition). p<0.05 will be considered statistically significant. | 1-Day Follow-UP |
| Less or equal severe adverse events in Group A compared to group B. p<0.05 will be considered statistically significant. | 1-Day Follow-UP |
| Easy of phacoemulsification as subjectively perceived by the surgeon during surgery | time fo surgery |
Countries
India
Outcome results
None listed